• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly October 2008

CenterWatch Monthly October 2008

October 3, 2008
CenterWatch Staff

Trio of Companies in Strategic Outsourcing Partnerships with Lilly

Eli Lilly’s recent agreement to sell an R&D facility to Covance is the largest and most comprehensive outsourcing deal in the CRO industry. Somewhat lost in the hoopla around the mega-Lilly-Covance deal, was that Lilly also cut similar agreements at the same time with Quintiles and i3 Statprobe.These agreements are indicative of major changes in the sponsor-CRO relationship as the pharmaceutical industry remains under pressure to cut drug development time and costs.

Replacing Declaration of Helsinki with GCP for Foreign Trials

The Good Clinical Practice (GCP) Guideline of the International Conference on Harmonisation is considered final guidance by FDA. Final guidance is considered a reflection of FDA’s current thinking on a subject.Up until October, FDA accepted non-IND foreign clinical studies, provided they were well-designed and well-conducted in accordance with ethical principles stated in the 1989 version of the Decleration of Helsinki or the laws and regulations of the country in which the research was conducted.

IMI and ECRIN Removing Bottlenecks of Drug Development in EU

The overall goal of the Innovative Medicine Initiative (IMI) and the European Clinical Research Infrastructure Network (ECRIN) is to remove the major bottlenecks in drug development where research is key. The European Commission (EC) has committed 1 billion euros to IMI, and the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade group representing the research-based pharmaceutical industry operating in Europe is committed to contributing resources that are at least equal to the EC’s. Both financial commitments are for the Seventh Framework Programme (FP7), which runs from 2007 to 2013, though IMI will run from 2008 to 2017.

Eye On: Breast Cancer

Breast cancer, which is the most common cancer among women worldwide, arises from breast tissues, typically from the ducts carrying milk to the nipple or the lobules that secrete milk. Although it occurs in both sexes, it is rare in men. Each year, more than 1 million new cases of breast cancer are diagnosed worldwide, and there are nearly 400,000 deaths from breast cancer. According to the National Cancer Institute, there will be 182,460 new cases of breast cancer in women and 1,990 in men in the United States in 2008, and 40,480 deaths in women and 450 in men.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing